

Appendix 1: Summary Table of Vaccination Recommendations

S/N	Recommendations																												
1.	<p>Two Vaccine Doses Recommended for Unvaccinated</p> <p>Persons aged 6 months and above are recommended to receive one of the following vaccines, with doses received 8 weeks apart:</p> <table border="1"> <thead> <tr> <th></th> <th>Vaccine</th> <th>Age</th> <th>Doses</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Pfizer-BioNTech/Comirnaty</td> <td>6 months to 4 years</td> <td>Two 3mcg doses</td> </tr> <tr> <td>2</td> <td>Pfizer-BioNTech/Comirnaty</td> <td>5 to 11 years</td> <td>Two 10mcg doses</td> </tr> <tr> <td>3</td> <td>Pfizer-BioNTech/Comirnaty</td> <td>12 years and above</td> <td>Two 30mcg doses</td> </tr> <tr> <td>4</td> <td>Moderna/Spikevax</td> <td>6 months to 11 years</td> <td>Two 25mcg doses</td> </tr> <tr> <td>5</td> <td>Moderna/Spikevax</td> <td>12 years and above</td> <td>Two 50mcg doses</td> </tr> <tr> <td>6</td> <td>Novavax/Nuvaxovid*</td> <td>12 years and above</td> <td>Two 5mcg doses</td> </tr> </tbody> </table> <p>Persons aged 18 years and above who are medically ineligible to complete the primary vaccination series with the mRNA vaccines or Novavax/Nuvaxovid vaccine may receive the Sinovac-CoronaVac vaccine to complete their primary series. These persons should receive a total of 2 doses of vaccines (inclusive of the mRNA vaccines or Novavax/Nuvaxovid vaccine) to complete their primary vaccination series.</p> <p>The recommended interval between doses is eight weeks. Individuals, particularly those who are at risk for exposure to COVID-19 or severe disease, may receive the second dose earlier than eight weeks after the first dose but not less than the minimum intervals (21 days for the Pfizer-BioNTech/Comirnaty and Novavax/Nuvaxovid vaccines and 28 days for Moderna/Spikevax and Sinovac-CoronaVac vaccines).</p> <p>* The Novavax/Nuvaxovid vaccine is currently unavailable under the National Vaccination Programme. Novavax is in the process of filing for regulatory approval for its updated COVID-19 XBB.1.5 vaccine formulation.</p>		Vaccine	Age	Doses	1	Pfizer-BioNTech/Comirnaty	6 months to 4 years	Two 3mcg doses	2	Pfizer-BioNTech/Comirnaty	5 to 11 years	Two 10mcg doses	3	Pfizer-BioNTech/Comirnaty	12 years and above	Two 30mcg doses	4	Moderna/Spikevax	6 months to 11 years	Two 25mcg doses	5	Moderna/Spikevax	12 years and above	Two 50mcg doses	6	Novavax/Nuvaxovid*	12 years and above	Two 5mcg doses
	Vaccine	Age	Doses																										
1	Pfizer-BioNTech/Comirnaty	6 months to 4 years	Two 3mcg doses																										
2	Pfizer-BioNTech/Comirnaty	5 to 11 years	Two 10mcg doses																										
3	Pfizer-BioNTech/Comirnaty	12 years and above	Two 30mcg doses																										
4	Moderna/Spikevax	6 months to 11 years	Two 25mcg doses																										
5	Moderna/Spikevax	12 years and above	Two 50mcg doses																										
6	Novavax/Nuvaxovid*	12 years and above	Two 5mcg doses																										
2.	<p>Enhanced Primary Series for Immunocompromised</p> <p>Persons with moderate to severe immunocompromise are recommended to receive a total of three doses of the mRNA vaccines). This comprises a third primary vaccine dose two months after the second dose as part of an enhanced three-dose primary series. This includes persons with the following conditions:</p> <ol style="list-style-type: none"> Transplant patients on immunosuppressive therapy, including solid organ and allogenic stem cell transplants Cancer patients on active treatment with chemotherapy and immunosuppressive therapy Haematological cancers 																												

	<ul style="list-style-type: none"> d. Immunosuppressive treatment for non-cancer conditions e. End-stage kidney disease f. Advanced or untreated HIV <p>Children aged 6 months to 4 years who are immunocompromised are recommended to receive an enhanced primary series comprising three doses of the Moderna/Spikevax vaccine or Pfizer-BioNTech/Comirnaty vaccine.</p>
3.	<p>Additional Dose for Year 2023/2024</p> <p>After having completed the recommended doses above and any other additional doses previously (where applicable), persons aged 6 months and above may receive in 2023/2024, one additional dose of COVID-19 vaccine at an interval of around 1 year (minimally 5 months) after their last dose. The additional dose is:</p> <ul style="list-style-type: none"> a. Recommended for all persons aged 60 years and above, medically vulnerable individuals and residents of aged care facilities; b. Encouraged for all individuals aged 6 months and above, in particular, healthcare workers, as well as household members / caregivers of medically vulnerable individuals <p>Immunocompromised persons can be considered to receive the additional dose of COVID-19 vaccine from 5 months after their last dose in consultation with their treating physician for better protection.</p>
4.	<p>Persons who Have Recovered from COVID-19</p> <p>Recovered persons who were unvaccinated, or partially vaccinated before their infection can proceed to complete the standard primary vaccination series. They are recommended to receive remaining vaccine doses from 3 months or more after the date of infection to reduce their risk of reinfection.</p> <p>Recovered persons who are recommended to receive an additional COVID-19 vaccine dose after their last vaccine dose should do so at the recommended interval thereafter, and at least 28 days after the infection although an interval of three months from the infection is recommended for better effectiveness.</p>

Appendix 2: Common Examples of Allergies and Guidance for COVID-19 Vaccination

Allergy Information	Vaccination Decision
25/M with urticaria to penicillin and cephalosporins. Had history of throat swelling, shortness of breath and dizziness, no ulcers.	Can vaccinate Persons with anaphylaxis to drugs/medications can be vaccinated.
35/F with hives to ibuprofen and celecoxib. <u>Had throat swelling</u> with celecoxib and some <u>dizziness</u> .	Can vaccinate Persons with anaphylactoid reactions can be vaccinated
45/F with eye and lip swelling to naproxen and paracetamol. No throat swelling, no shortness of breath, no dizziness, no ulcers. No history of anaphylaxis or Epi-Pen use.	Can vaccinate Persons with drugs/medications allergies can be vaccinated
35/M with hives that started <u>8 hours after</u> first dose of mRNA-COVID-19 vaccine. No throat swelling, no shortness of breath, no dizziness. Did not see a doctor. Rash took 2 days to resolve with antihistamines.	Can vaccinate Persons with non-severe skin reaction occurring more than four hours after vaccination
35/F with fever and arm swelling after first dose of COVID-19 vaccine. Injection site erythema and swelling was approximately 6 cm.	Can vaccinate Non-allergic side effect.
45/F with rash on limbs after eating crab. No throat swelling, no shortness of breath, no dizziness. Resolved in half a day.	Can vaccinate Persons with food allergies can be vaccinated
30/F with shortness of breath and dizziness after eating peanuts. Used Epi-Pen to resolve symptoms	Can vaccinate Persons with anaphylaxis to food can be vaccinated. History of Epi-pen usage can be vaccinated
55/M with diabetes, <u>SJS</u> to Bactrim. Severe rash, with lip ulceration, admitted for a week for SJS. No throat swelling, no shortness of breath, no dizziness.	Can vaccinate SJS is not a contraindication

55/F with HIV, also macular-papular rash to Bactrim CD4 = 540 cells/mm ³ , virologically controlled. No throat swelling, no shortness of breath, no dizziness, no ulcers	Can vaccinate Allergy is not anaphylaxis
--	--

M – Male

F – Female

SJS – Steven-Johnson Syndrome

Appendix 3: List of Medical Conditions for Which Persons are Considered Medically Vulnerable to Severe COVID-19 (current as of 26 October 2023)

The Expert Committee on COVID-19 Vaccination has recommended that medically vulnerable persons who are at higher risk of severe disease due to medical risk factors should receive an additional dose of COVID-19 vaccine in 2023/2024, at an interval of one year after the last dose.

Persons with the following conditions are recommended to receive the additional dose in 2023/2024:

1. Diabetes
2. Heart conditions such as heart failure, ischemic heart disease, cardiomyopathy
3. Chronic lung conditions, including severe asthma
4. Chronic liver conditions, including cirrhosis
5. Chronic kidney conditions, including dialysis
6. Chronic neurologic conditions, including stroke
7. Cancer on active treatment
8. Blood conditions such as thalassemia and sickle cell anemia
9. Immunodeficiencies, including HIV infection
10. Obesity (BMI \geq 30)
11. Genetic or metabolic conditions, including Down's syndrome and cystic fibrosis
12. Persons on non-cancer immunosuppressive treatment
13. Pregnancy (any trimester)